Talapro-2: A 2-part, placebo-controlled phase 3 study of talazoparib (TALA) with background enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC) with DNA damage repair deficiencies. Meeting Abstract

cited authors

  • Agarwal, Neeraj; Azad, Arun; Fay, Andre; Carles, Joan; Shore, Neal D.; Nordquist, Luke T.; Karsh, Lawrence Ivan; Dunshee, Curtis; Nandakumar, Srinand Ponnathapura; Sullivan, Beth; Czibere, Akos; Wang, Fong; Fizazi, Karim

Publication Date

  • May 20, 2018

webpage

published in

category

volume

  • 36

issue

  • 15